- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.05. | OSR Holdings, Inc. - S-1, General form for registration of securities | 3 | SEC Filings | ||
| OSR HOLDINGS Aktie jetzt für 0€ handeln | |||||
| 26.05. | UKGC Welcomes OSR Review of Gambling Survey for Great Britain | 3 | European Gaming | ||
| 20.05. | OSR Holdings, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 15.05. | OSR Holdings, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 5 | SEC Filings | ||
| 22.04. | OSR Holdings, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 03.04. | OSR Signs $80 Mln Stock Purchase Agreement With White Lion GBM Innovation Fund, Stock Up | 2 | RTTNews | ||
| 03.04. | OSR Holdings enters $80 mln stock purchase agreement with White Lion GBM Innovation Fund | 2 | Seeking Alpha | ||
| 03.04. | OSR Holdings secures $80 million funding option for cancer therapy | 1 | Investing.com | ||
| 03.04. | OSR Holdings sichert sich 80 Millionen US-Dollar Finanzierungsoption für Krebstherapie | 3 | Investing.com Deutsch | ||
| 03.04. | OSR Holdings Inc.: OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate ... | 112 | PR Newswire | SEOUL, South Korea, April 3, 2025 /PRNewswire/ -- OSR Holdings, Inc. ("OSR") (NASDAQ: OSRH), a global healthcare company focused on advancing innovative therapies... ► Artikel lesen | |
| 01.04. | OSR Holdings, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 1 | SEC Filings | ||
| 26.03. | Pre-market Movers: OSR Holdings, SurgePays, Beeline Holdings, Humacyte, Tenon Medical | 644 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.45 A.M. ET).In the Green OSR Holdings, Inc. (OSRH) is up over 173% at $4.37.
SurgePays... ► Artikel lesen | |
| 26.03. | OSR Holdings Inc.: Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma | 168 | PR Newswire | Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in Glioblastoma, supporting further investigation... ► Artikel lesen | |
| 25.03. | OSR Holdings Inc.: OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer | 173 | PR Newswire | BASEL, Switzerland, March 25, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and... ► Artikel lesen | |
| 25.03. | OSR Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.03. | OSRH-Aktie stürzt | 2 | Investing.com Deutsch | ||
| 21.02. | OSR Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.02. | Pre-market Movers: Sintx Technologies, Cycurion, OSR Holdings, ReShape Lifesciences, NewGenIvf Group | 661 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 07.35 A.M. ET).In the Green Sintx Technologies, Inc. (SINT) is up over 87%... ► Artikel lesen | |
| 18.02. | NSE - OSR Holdings, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 1 | SEC Filings | ||
| 15.02. | OSR Holdings Inc.: OSR Holdings, Inc. and OSR Holdings Co., Ltd. Announce Completion of Business Combination | 201 | PR Newswire | OSR Holdings, Inc. to Begin Trading on the Nasdaq Stock Market LLC on Tuesday, February 18, 2025 Under the symbol "OSRH"
SEOUL, South Korea, Feb. 14, 2025 /PRNewswire/... ► Artikel lesen |
Seite:
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SPRINGWORKS THERAPEUTICS | 46,710 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics erhält positive CHMP-Stellungnahme für Mirdametinib zur Behandlung erwachsener und pädiatrischer Patienten mit NF1-PN | - im Falle einer Marktzulassung wäre Mirdametinib die erste und einzige Behandlung in der Europäischen Union für Erwachsene und Kinder mit NF1-PN -
- die Entscheidung der Europäischen Kommission... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 34,220 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 15,520 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
| ARCELLX | 65,48 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 28,880 | 0,00 % | Kiniksa Pharmaceuticals International, plc - 8-K, Current Report | ||
| BIONTECH | 99,00 | +1,54 % | BioNTech: Milliardendeal mit Bristol Myers Squibb - Aktie schießt ins Plus | BioNTechs Aktien schießen in der US-Vorbörse am Montag regelrecht nach oben: Aktuell werden 106,10 Dollar notiert nach einem NASDAQ-Schlusskurs bei 95,81 Dollar vom Freitag. Der Grund für den Kursanstieg... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 22,290 | 0,00 % | Mizuho erhöht Kursziel für Enliven Therapeutics-Aktie auf 41 US-Dollar | ||
| DISC MEDICINE | 47,320 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update | Company remains on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025Initiated APOLLO, a confirmatory clinical trial of bitopertin in adults and adolescents with... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 36,500 | 0,00 % | Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results | Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling First patient dosed in Phase 1b trial of APG777 in... ► Artikel lesen | |
| ADMA BIOLOGICS | 20,330 | -0,64 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| QIAGEN | 40,300 | -0,06 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Qiagen mit einem Kursziel von 48 Euro auf "Buy" belassen. Der Tenor auf der Berenberg-MedTech-Investorenkonferenz in Manhatten... ► Artikel lesen | |
| 89BIO | 10,050 | 0,00 % | 89bio hält Jahreshauptversammlung ab, Direktoren gewählt | ||
| ARCUTIS BIOTHERAPEUTICS | 13,260 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung und 19 US-Dollar Kursziel für Arcutis-Aktie | ||
| KYMERA THERAPEUTICS | 44,310 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader | Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera's target product profile, significantly derisking program and further validating its oral, biologics-like profile... ► Artikel lesen | |
| FULCRUM THERAPEUTICS | 7,030 | 0,00 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics to Present at Upcoming Medical Meetings |
Das Unternehmen OSR HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,390 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OSR HOLDINGS INC finden Sie auf Wallstreet Online.